Asthma Clinical Trial
Official title:
Exploring a Cessation Intervention for Low Income Smokers in an Emergency Setting
| Verified date | August 2017 |
| Source | Children's Hospital Medical Center, Cincinnati |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
An estimated 6.6 million parents who smoke visit pediatric emergency departments (PED)
annually. Up to 50% of these parental smokers are from low-income, racially/ethnically
diverse households in which a variety of tobacco-related disparities (TRD) exist for both the
parents and their children. The PED is an ideal setting in which to address these
disparities, which include differences in tobacco use, pediatric second hand smoke exposure
(SHSe), quit rates, access to cessation resources, and morbidity such as cancer. The team has
conducted the only two small-scale randomized control trials (RCTs) investigating the
efficacy of providing smoking cessation counseling to parents in the PED setting. This
previous research indicates that parental smokers who visit the PED are aware of the
pediatric effects of SHSe, motivated to quit, eager to receive cessation counseling in this
setting, and show trends towards quitting.
Parents with children who have a SHSe-related illness will have higher prolonged abstinence
and point prevalence cessation rates, higher motivation to quit, greater number of quit
attempts, and lower child SHSe compared to those parents who have a child with a
non-SHSe-related illness at baseline.
| Status | Completed |
| Enrollment | 230 |
| Est. completion date | March 2016 |
| Est. primary completion date | July 2014 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | N/A and older |
| Eligibility |
Phase 1: Focused Interviews of Pediatric Emergency Department Practitioners will be
conducted to assess their perceived attitudes and barriers to implementing routine tobacco
screening and tobacco counseling in the pediatric emergency department. Inclusion Criteria: - Hospital personnel: PED medical director, Chief of Staff, Chairman of Pediatrics, quality systems specialists, informational technology specialists, PED physicians, and PED registered nurses. Exclusion Criteria: - Non-hospital personnel Phase 2: Parental smokers who bring their children to the pediatric emergency department will be given brief smoking cessation counseling which includes advice on quitting, nicotine replacement therapy vouchers and direct Quitline connection. Inclusion Criteria: - Parent/Legal Guardian (18 years or older), who are tobacco users, accompanying a child (0 to 18 years old) being treated in the PED with a non-urgent complaint/condition. Exclusion Criteria: - Parent/Legal Guardian who is only a tobacco chewer. - Parent/Legal Guardian who is enrolled in a smoking cessation program. - Parent/Legal Guardian who is using Nicotine Replacement Therapy (NRT) or other cessation treatment. - Parent/Legal Guardian who is moving within 8 months after enrollment. Phase 3: The same PED-based SBIRT cessation intervention will be given to these parental smokers as in Phase 2. However, parents will also be asked if they agree to have their child participate in saliva sample collection at baseline and at one month. Parents will also be asked if their child's leftover saliva can be stored for future research. Inclusion Criteria: - Parent/Legal Guardian (18 years or older), who are tobacco users, accompanying a child (0 to 5 years old) being treated in the PED with a non-urgent second hand smoke exposure related complaint/condition. Exclusion Criteria: - Parent/Legal Guardian who is only a tobacco chewer. - Parent/Legal Guardian who is enrolled in a smoking cessation program. - Parent/Legal Guardian who is using Nicotine Replacement Therapy (NRT) or other cessation treatment. - Parent/Legal Guardian who is moving within 8 months after enrollment - Parent/Legal Guardian who does not speak or read English |
| Country | Name | City | State |
|---|---|---|---|
| United States | Cincinnati Children's Hospital Medical Center | Cincinnati | Ohio |
| Lead Sponsor | Collaborator |
|---|---|
| Children's Hospital Medical Center, Cincinnati | National Cancer Institute (NCI) |
United States,
Mahabee-Gittens EM, Khoury JC, Ho M, Stone L, Gordon JS. A smoking cessation intervention for low-income smokers in the ED. Am J Emerg Med. 2015 Aug;33(8):1056-61. doi: 10.1016/j.ajem.2015.04.058. Epub 2015 May 2. — View Citation
Mahabee-Gittens EM, Stone L, Gordon JS. Pediatric emergency department is a promising venue for adult tobacco cessation interventions. Nicotine Tob Res. 2013 Oct;15(10):1792-3. doi: 10.1093/ntr/ntt069. Epub 2013 May 24. — View Citation
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Parents who report that they have not smoked in the past seven (7) days, and their verbal response is verified by a carbon monoxide test. | Approximately 2 years |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
| Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
| Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
| Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
| Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
| Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
| Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
| Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
| Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
| Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
| Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
| Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
| Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
| Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
| Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
| Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
| Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
| Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
| Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
| Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|